Kush M. Parmar

Kush is a Managing Partner at 5AM Ventures. He also serves as Co-Chief Executive Officer and as member of the Board of Directors of 5:01 Acquisition Corp. Kush serves as a board member of Akouos, Inc., Entrada Therapeutics, Inc., Ensoma Inc., Homology Medicines, Inc., Vor Biopharma Inc., and Syngene International Limited, and previously served on the board of directors of Arvinas, Inc., Audentes Therapeutics, Inc., and scPharmaceuticals, Inc. He also serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. Kush is a Fellow of the Society of Kauffman Fellows. Prior to 5AM, Kush was at Harvard Medical School, where he was an NIH-sponsored MD/PhD Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program.

Kush earned a B.A. in molecular biology and medieval studies from Princeton University, a Ph.D. in experimental pathology from Harvard University, and an M.D. from Harvard Medical School.